Table 2.
MicroRNAs in clinical trials.
| Name (Company) |
Therapeutic Agent | Target Diseases | Trial Details | Clinical Trials.Gov Identifier | Reference |
|---|---|---|---|---|---|
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) |
Anti-miR-122 | Hepatitis C (chronic infections included) |
Phase III, completed | NCT01728324 | [78,135] |
| Phase III, completed | NCT01366638 | ||||
| Phase IV, completed | NCT01222611 | ||||
| Phase II, completed | NCT00996476 | ||||
| Phase III, completed | NCT01725529 | ||||
| Phase III, completed | NCT01290731 | ||||
| Phase III, completed | NCT01292239 | ||||
| Phase III, completed | NCT01288209 | ||||
| metastatic soft tissue sarcoma | Phase II, completed | NCT00413192 | [139] | ||
| Cobomarsen or MRG-106 (miRagen Therapeutics) | Anti-miR-155 | cutaneous T-lymphoma, Alibell’s disease, chronic lymphocytic leukemia and adult T-cell leukemia and lymphoma | Phase I, completed | NCT02580552 | [146] |
| CDR132L | miR-132 inhibitor | heart disease | Phase I, completed | NCT04045405 | [149] |
| MRX34 (Mirna Therapeutics) | miR-34 mimic | multiple solid tumours | Multicentre phase I, terminated | NCT01829971 | [141,142,143,144,145] |
| MesomiR-1 (EnGeneIC) | miR-16 mimic | mesothelioma, non-small cell lung cancer |
Phase I, completed | NCT02369198 | [135] |
| Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Recruiting | NCT03766204 |